View ValuationSCHOTT Pharma KGaA 将来の成長Future 基準チェック /16SCHOTT Pharma KGaA利益と収益がそれぞれ年間9.4%と6.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に14.2% 9.2%なると予測されています。主要情報9.4%収益成長率9.25%EPS成長率Life Sciences 収益成長20.2%収益成長率6.1%将来の株主資本利益率14.17%アナリストカバレッジGood最終更新日22 May 2026今後の成長に関する最新情報Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.すべての更新を表示Recent updatesお知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.Declared Dividend • Dec 30Dividend increased to €0.18Dividend of €0.18 is 13% higher than last year. Ex-date: 4th February 2026 Payment date: 6th February 2026 Dividend yield will be 1.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (19% earnings payout ratio) and cash flows (77% cash payout ratio). The dividend has increased by an average of 9.5% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.お知らせ • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025お知らせ • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026お知らせ • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026お知らせ • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.お知らせ • Dec 19SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025, at 10:00 W. Europe Standard Time.お知らせ • Nov 16+ 3 more updatesSCHOTT Pharma AG & Co. KGaA to Report First Half, 2025 Results on May 15, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2025 results on May 15, 2025お知らせ • Sep 05SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2024 Results on Dec 12, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2024 results on Dec 12, 2024Reported Earnings • Aug 30Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: €0.31 (up from €0.20 in 3Q 2023). Revenue: €253.6m (up 15% from 3Q 2023). Net income: €46.3m (up 52% from 3Q 2023). Profit margin: 18% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) also surpassed analyst estimates by 52%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €36.18, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €46.51 per share.Reported Earnings • Jun 28Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: EPS: €0.17. Net income: €25.0m (up €25.0m from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €31.78, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €47.63 per share.Reported Earnings • Mar 03First quarter 2024 earnings released: EPS: €0.29 (vs €0.17 in 1Q 2023)First quarter 2024 results: EPS: €0.29 (up from €0.17 in 1Q 2023). Revenue: €232.3m (up 14% from 1Q 2023). Net income: €44.4m (up 74% from 1Q 2023). Profit margin: 19% (up from 13% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.Buy Or Sell Opportunity • Feb 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to €42.60. The fair value is estimated to be €35.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.お知らせ • Feb 27+ 1 more updateSCHOTT Pharma AG & Co. KGaA to Report First Half, 2024 Results on Feb 29, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2024 results on Feb 29, 2024Buy Or Sell Opportunity • Feb 01Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 30% to €36.80. The fair value is estimated to be €30.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.お知らせ • Sep 29SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million.SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 7,407,407 Price\Range: €27 Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 22,715,517 Price\Range: €27 Transaction Features: Regulation S; Rule 144A業績と収益の成長予測DB:1SXP - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20281,15817810926499/30/20271,08716184239119/30/20261,0131439022693/31/202699114359202N/A12/31/202599515011158N/A9/30/202598614635180N/A6/30/202597714749203N/A3/31/202597414866206N/A12/31/202495613546184N/A9/30/202495715079225N/A6/30/202494915022191N/A3/31/2024916135-3175N/A12/31/202390615836220N/A9/30/20238991526182N/A6/30/202387314372217N/A9/30/202282112529182N/A9/30/202164910134132N/A9/30/20205847719104N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1SXPの予測収益成長率 (年間9.4% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: 1SXPの収益 ( 9.4% ) German市場 ( 17.1% ) よりも低い成長が予測されています。高成長収益: 1SXPの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 1SXPの収益 ( 6.1% ) German市場 ( 6.7% ) よりも低い成長が予測されています。高い収益成長: 1SXPの収益 ( 6.1% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1SXPの 自己資本利益率 は、3年後には低くなると予測されています ( 14.2 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 11:29終値2026/06/09 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SCHOTT Pharma AG & Co. KGaA 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23 アナリスト機関Gaurav JainBarclaysPallav MittalBarclaysJonathon UnwinBarclays20 その他のアナリストを表示
Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
お知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.
Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
Declared Dividend • Dec 30Dividend increased to €0.18Dividend of €0.18 is 13% higher than last year. Ex-date: 4th February 2026 Payment date: 6th February 2026 Dividend yield will be 1.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (19% earnings payout ratio) and cash flows (77% cash payout ratio). The dividend has increased by an average of 9.5% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.
お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.
お知らせ • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025
お知らせ • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026
お知らせ • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026
お知らせ • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.
お知らせ • Dec 19SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Nov 16+ 3 more updatesSCHOTT Pharma AG & Co. KGaA to Report First Half, 2025 Results on May 15, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2025 results on May 15, 2025
お知らせ • Sep 05SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2024 Results on Dec 12, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2024 results on Dec 12, 2024
Reported Earnings • Aug 30Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: €0.31 (up from €0.20 in 3Q 2023). Revenue: €253.6m (up 15% from 3Q 2023). Net income: €46.3m (up 52% from 3Q 2023). Profit margin: 18% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) also surpassed analyst estimates by 52%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €36.18, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €46.51 per share.
Reported Earnings • Jun 28Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: EPS: €0.17. Net income: €25.0m (up €25.0m from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €31.78, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €47.63 per share.
Reported Earnings • Mar 03First quarter 2024 earnings released: EPS: €0.29 (vs €0.17 in 1Q 2023)First quarter 2024 results: EPS: €0.29 (up from €0.17 in 1Q 2023). Revenue: €232.3m (up 14% from 1Q 2023). Net income: €44.4m (up 74% from 1Q 2023). Profit margin: 19% (up from 13% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Buy Or Sell Opportunity • Feb 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to €42.60. The fair value is estimated to be €35.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
お知らせ • Feb 27+ 1 more updateSCHOTT Pharma AG & Co. KGaA to Report First Half, 2024 Results on Feb 29, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2024 results on Feb 29, 2024
Buy Or Sell Opportunity • Feb 01Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 30% to €36.80. The fair value is estimated to be €30.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
お知らせ • Sep 29SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million.SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 7,407,407 Price\Range: €27 Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 22,715,517 Price\Range: €27 Transaction Features: Regulation S; Rule 144A